Table 4 Clinical response and associated adverse events
|  | Total, n = 38 | ST group, n = 20 | MT group, n = 18 | P |
|---|---|---|---|---|
Positive of clinical response [%, no.] | 84.21(32/38) | 100.00(20/20) | 66.70(12/18) | 0.026* |
Duration of hospital stay | 20.50(10.75–31.25) | 30.00(10.50–42.50) | 15.00(9.00-22.25) | 0.059 |
Duration of fever | 8.00(6.00-10.25) | 7.00(5.00-8.75) | 11.50(8.00-16.25) | 0.029* |
Dose of TMP, mg/kg/day | 16.55(15.69–18.67) | 15.71(14.23–16.43) | 18.35(16.48–19.40) | 0.001* |
All-cause mortality,% | 21.05(8/38) | 25.00(5/20) | 16.67(3/18) | 0.277 |
All adverse effects [%, no.] | 31.58(12/38) | 15.00(3/20) | 50.00(9/18) | 0.022* |
Nausea/Vomiting [%, no.] | 10.53(4/38) | 5.00(1/20) | 16.67(3/18) | Â |
Hyperkaliemia [%, no.] | 7.89(3/38) | 5.00(1/20) | 11.11(2/18) | Â |
Diarrhea [%, no.] | 7.89(3/38) | 0.00(0/20) | 16.67(3/18) | Â |
Thrombocytopenia [%, no.] | 2.63(1/38) | 5.00(1/20) | 0.00(0/18) | Â |
Drug eruption [%, no.] | 2.63(1/38) | 0.00(0/20) | 5.56(1/18) | Â |